搜索结果
靶点ID:TCMBANKGE002442
靶点别名:CALJA; CD73; E5NT; NT; NT5; NTE; eN; eNT
靶点描述:5'-nucleotidase ecto
染色体:6
染色体位置:6q14.3
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:8021
OMIM_Link:129190
Ensembl_Link:ENSG00000135318
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN012700 | coumestrol | NCIMech_000078; CCRIS 7311; A-Lactone; API0002121; Tox21_200032; MolPort-003-846-031; US8552057, 3; HMS3374A07; 3,9-Dihydroxy-6H-benzofuro[3,2-c]-[1]benzopyran-6-one; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,3,9-dihydroxy-; Cumostrol; CHEBI:3908; C-16836; VZ31590; LS-35394; S00280; 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one; MFCD00016885; SMP2_000163; DSSTox_RID_76572; 27885_FLUKA; 6H-Benzofuro[3, 3,9-dihydroxy-; 5-19-06-00405 (Beilstein Handbook Reference); BRN 0266702; 479-13-0; NSC22842; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone; C10205; 3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one; AC1NQYXV; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone (6CI); NCGC00018124-01; DSSTox_CID_2399; CTK8F8799; Coumestrol, >=95.0% (HPLC); NCI60_001863; 4CN-2508; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; BIDD:ER0114; NCGC00018124-03; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one #; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; A1-00298; NSC 22842; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; CCG-35536; NCGC00018124-06; 3,9-bis(oxidanyl)-[1]benzofuro[3,2-c]chromen-6-one; ZINC1219; NCGC00257586-01; 3,9-Dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one; AIDS011954; SCHEMBL22012; UNII-V7NW98OB34; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; MLS000069446; CCG-36200; LMPK12090018; 3-Benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 7,12-Dihydroxycoumestan; CS-6343; D02DML; CHEMBL30707; 3,9-dihydroxy-6-benzofurano[3,2-c]chromenone; ZINC00001219; 5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one; Oprea1_222511; MLS000738006; EINECS 207-525-6; 3,9-Dihydroxycoumestan; Coumestrol, BioReagent, suitable for fluorescence, >=97.5% (HPLC); A827386; DTXSID6022399; CAS-479-13-0; FT-0603177; ST50320052; 2-(2,4-Dihydroxyphenyl)-6-hydroxy-3-benzofurancarboxylic Acid ; 3,9-dihydroxybenzofurano[3,2-c]chromen-6-one; 3,9-dihydroxybenzo[d]chromeno[4,3-b]furan-6-one; NCGC00023462-03; AIDS-011954; V0359; Cumoestrol; DSSTox_GSID_22399; Cumoesterol; NCGC00018124-05; Coumestrol; NCGC00018124-04; V7NW98OB34; ZB000278; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; ST5320052; AN-6463; Cumestrol; NCGC00023462-04; NCGC00018124-02; CC-25990; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-; NSC-22842; 3,9-dihydroxybenzofuro[3,2-c]chromen-6-one; AKOS028111776; HMS2235B05; Coumesterol; COUMESTROL; BDBM23451; SMR000059001; HY-N2335; 27883_FLUKA | C15H8O5 | 268.22 | C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O |
| TCMBANKIN017156 | hypoxanthine-9-β-D-ribofuranoside | C10H12N4O5 | C1=NC(=O)C2=C(N1)N(C=N2)C3C(C(C(O3)CO)O)O | ||
| TCMBANKIN033702 | citric acid | InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850 | C6H8O7 | 192.12 | C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
| TCMBANKIN035814 | (7E)-9-hydroxymegastigma-4, 7-dien-3-on-9-O-beta-D-glucopyranoside_qt | 208.33 | |||
| TCMBANKIN055948 | Eupachlorin acetate | enoxaparin;nadroparin | C22H27ClO8 | 420.453 | [C@]12([H])[C@](O[H])(C(C([H])([H])[H])=C([H])[C@@]1([H])OC(=O)C([H])([H])[H])[C@]3([H])[C@]([H])(C(=C([H])[H])C(=O)O3)[C@]([H])(OC(=O)\C(\C([H])([H])[H])=C([H])/C([H])([H])[H])C([H])([H])[C@]2(O[H])C ([H])([H])Cl |
| TCMBANKIN057905 | ferrum | iron | Fe | 55.84 g/mol | [Fe] |
| TCMBANKIN058450 | ADO | nchembio.2007.56-comp13; CHEBI:16335; Bio1_000437; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; AIDS-001224; 9beta-D-Ribofuranosyladenine; BSPBio_001796; beta-Adenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol; beta-D-Ribofuranoside, adenine-9; D00045; 46969-16-8; SDCCGMLS-0003108.P003; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; NSC 7652; Bio1_001415; Adenosine (JAN/USP); Spectrum2_001257; Spectrum3_000288; Adenosine, homopolymer; ADN; Caswell No. 010B; Adenocard; C00212; SR 96225; Adenocard (TN); EINECS 200-389-9; KBio3_001296; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; Polyadenosine; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; (2R,3R,4S,5R)-2-(6-amino-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; MLS000069638; AI3-52413; 9-beta-D-Ribofuranosidoadenine; A9251_SIGMA; Adenoscan (TN); Bio1_000926; ZINC02169830; CCRIS 2557; NCGC00023673-05; Ade-Rib; nchembio706-5; 30143-02-3; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Adenosin [German]; NSC 627048; SMR000058216; 9-beta-D-Ribofuranosyladenine; SPBio_001194; beta-D-Adenosine; Adenosine [USAN:BAN]; Polyriboadenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; AIDS001224; 6-Amino-9beta-D-ribofuranosyl-9H-purine; ST009496; Adenoscan; A4036_SIGMA; SPECTRUM1500107; 46946-45-6;SCHEMBL170902; adenosine ; AKOS015960342; AC-5504; BC200893; Adenosine;adenosine;adeninenucleoside | C10H13N5O4 | 267.24 g/mol | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N |
| TCMBANKIN058453 | inosine | 962ABA7D-F602-497D-AD86-94526094D87E; EINECS 200-390-4; I4125_SIGMA; Panholic-L; Inosina [INN-Spanish]; AIDS-008385; Hypoxanthine ribonucleoside; Hypoxanthosine; CHEBI:17596; KBioGR_002560; 12712-98-0; KBio2_007696; BB_NC-0564; Atorel; 1,9-Dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-tetrahydrofuranyl]-3H-purin-6-one; beta-Inosine; Hypoxanthine 9-beta-D-ribofuranoside; Ribonosine; MLS000028518; ST5308705; Inosine (8CI,9CI); 6H-Purin-6-one, 1,9-dihydro-9-beta-D-ribofuranosyl-; Trophicardyl; SMP1_000165; InChI=1/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s; Inotin; 132953-54-9; KBioSS_002569; ZINC05127790; AI3-52241; 9-beta-D-ribofuranosyl-9H-purin-6-ol; Inosine (JAN/INN); Hypoxanthine riboside; Oxiamin; Hypoxanthine D-riboside; Inosinum [INN-Latin]; HXR; INO 495; KBio2_005128; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one; KBio3_003038; 28861-88-3; 9-beta-D-Ribofuranosylhypoxanthine; Inosin; Inotin (TN); C00294; beta-D-Ribofuranoside, hypoxanthine-9; (-)-Inosine; ZINC02169852; SMR000058316; KBio2_002560; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-3H-purin-6-one; cMAP_000084; D00054; Hypoxanthine nucleoside; AIDS008385; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one; Pantholic-L; Inosine [INN:JAN]; Selfer; 4181-51-5; NSC 20262; Hypoxanthine, 9-beta-D-ribofuranosyl-; (−)-Inosine; hypoxanthinenucleoside; NOS | C10H12N4O5 | 268.23g/mol | C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O |
| TCMBANKIN058500 | DUR | D5412_SIGMA; AIDS113822; ZINC00155696; BRN 0024433; 4-24-00-01200 (Beilstein Handbook Reference); 1-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1-H-pyrimidine-2,4-dione; NCGC00142492-01; 2'-Deoxyuridine; 1-[(2R,4S,5R)-4-hydroxy-5-methylol-tetrahydrofuran-2-yl]pyrimidine-2,4-quinone; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; C00526; CCRIS 2832; AIDS-113822; MLS001066344; dURD; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-erythro-ribofuranosyl)-; NSC 23615; SMR000112296; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-tetrahydrofuranyl]pyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; 20649-53-0; ST057093; EINECS 213-455-7; 2′-Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; deoxyuridine | C9H12N2O5 | 228.2 g/mol | C1C(C(OC1N2C=CC(=O)NC2=O)CO)O |
| TCMBANKIN058964 | heparin | enoxaparin;nadroparin | C26H42N2O37S5 | 1134.9 g/mol | CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI000044 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000092 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000389 | Pathological Conditions, Signs and Symptoms; Infections | - | Disease or Syndrome | phenotype | |
| TCMBANKDI000805 | Pathological Conditions, Signs and Symptoms; Infections; Respiratory Tract Diseases; Otorhinolaryngologic Diseases | Abnormality of head or neck | Sign or Symptom | phenotype | |
| TCMBANKDI002512 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI002606 | Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases | Abnormality of the respiratory system | Sign or Symptom | phenotype | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003115 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI003177 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003362 | Infections; Respiratory Tract Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI004222 | Eye Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI004646 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI006383 | Nervous System Diseases | - | Sign or Symptom | phenotype | |
| TCMBANKDI006612 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI007091 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI007832 | Cardiovascular Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI008255 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI008867 | Otorhinolaryngologic Diseases | Abnormality of the immune system; Abnormality of the ear | Disease or Syndrome | disease | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009244 | Infections; Respiratory Tract Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI009489 | - | - | Sign or Symptom | phenotype | |
| TCMBANKDI009827 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Respiratory Tract Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases | Abnormality of head or neck | Congenital Abnormality | disease | |
| TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI010160 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI010214 | - | - | Neoplastic Process | disease | |
| TCMBANKDI010306 | - | Abnormality of the skeletal system | Anatomical Abnormality | phenotype | |
| TCMBANKDI010514 | - | Abnormality of metabolism/homeostasis | Finding | phenotype | |
| TCMBANKDI010935 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011608 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI011814 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI012932 | Infections; Immune System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI013367 | Pathological Conditions, Signs and Symptoms; Digestive System Diseases; Otorhinolaryngologic Diseases | Abnormality of the digestive system | Sign or Symptom | phenotype | |
| TCMBANKDI015238 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015336 | - | - | Disease or Syndrome | phenotype | |
| TCMBANKDI015475 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI016429 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI016439 | Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI016641 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI016800 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI018093 | Pathological Conditions, Signs and Symptoms | Constitutional symptom | Sign or Symptom | phenotype | |
| TCMBANKDI018635 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI019066 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI019154 | Musculoskeletal Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI019307 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI019879 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI020743 | Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI020782 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI020794 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI020911 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI021315 | Pathological Conditions, Signs and Symptoms; Neoplasms; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI021346 | Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI021534 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI022473 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI022682 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | - | Neoplastic Process | disease | |
| TCMBANKDI023401 | Chemically-Induced Disorders; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI023412 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Immune System Diseases; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI025141 | Endocrine System Diseases | Abnormality of the endocrine system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI026013 | Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases; Nervous System Diseases; Mental Disorders; Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026360 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI026528 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026724 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI027040 | Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027684 | - | Abnormality of the cardiovascular system | Pathologic Function | phenotype | |
| TCMBANKDI028398 | Nutritional and Metabolic Diseases; Cardiovascular Diseases | Abnormality of the skeletal system; Abnormality of the cardiovascular system | Pathologic Function | phenotype | |
| TCMBANKDI028471 | Respiratory Tract Diseases; Otorhinolaryngologic Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI029265 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI029899 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI030204 | - | - | Neoplastic Process | disease | |
| TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI030664 | Respiratory Tract Diseases | Abnormality of metabolism/homeostasis; Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI031297 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI031651 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI032496 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab